Neupogen (filgrastim) / Kyowa Kirin, Amgen - LARVOL DELTA

Selinexor, Mezigdomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Relapsing / Ineligible for T-Cell-Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results (IMS 2026) - P1/2 | "Three pts relapsed after TCRT (3 cilta-cel; 2 talquetamab; 1 IGM-2644) and 4 after belantamab mafodotin, with 3 pts refractory to B-cell maturation antigen–targeted therapy. For the SMd all-oral combination, TEAEs were consistent with AE profiles for S and M, and no new safety signals were detected. The DLT of G4 neutropenia was manageable with filgrastim and dose reduction. Across all dose levels SMd showed efficacy in pts with heavily pretreated RRMM in whom TCRT had failed or who could not receive TCRT."

Clinical • IO biomarker • P1 data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CCR7 • CRBN • TIGIT • XPO1

Preemptive Tocilizumab in Patients with Relapsed-Refractory Multiple Myeloma Receiving Bispecific: A Case Series (IMS 2026) - "Teclistamab (Tec), talquetamab (Tal), and elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory multiple myeloma (RRMM)...All patients received intravenous immunoglobulin to maintain functional IgG ≥500 mg/dL, filgrastim to maintain absolute neutrophil 1.00 K/mcL, epoetin alfa to maintain hemoglobin above 10 g/dL, and romiplostim to maintain platelets above 50 K/mcL...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose of dexamethasone 10 mg... Preemptive Toci may decrease the incidence and severity of CRS in patients with RRMM receiving BsAbs, without compromising response. In this small observational analysis, no patients experienced prolonged hospitalization for management of CRS."

Bispecific • Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Optimising Elranatamab Treatment Delivery in Relapsed Refractory Multiple Myeloma: A Nurse Practitioner-Led Delivery Model at a Single Tertiary Centre. (IMS 2026) - "Patients received elranatamab step-up dosing during a 5-day inpatient admission or as an outpatient (n=3) with prophylactic tocilizumab...Adverse events included cytokine release syndrome (56%, all grade 1-2); multiple infections including cytomegalovirus with 24% requiring antiviral therapy; grade 4 neutropenia (56%) requiring regular filgrastim; skin toxicities including desquamation (11%) and injection site reactions (24%); and fatigue (68%)... A MMNP-led elranatamab delivery model is feasible, safe, and effective in the management of RRMM patients. Elranatamab achieves high response rates in heavily pre-treated patients, and an MMNP-led model enables rapid identification and management of adverse events. This model supports high-quality, coordinated care for both inpatient and outpatient step-up dosing with reduced healthcare resource use and cost burden for outpatient delivery."

Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Safety and Efficacy of G-CSF 'filgrastim BS' administration in the peripheral blood stem cell (PBSC) mobilization (clinicaltrials.gov) - P=N/A | N=20 | Completed | Sponsor: Div. Hematology and Div. Transfusion Medicine, Kanazawa University Hospital | Recruiting ➔ Completed

Trial completion • Transplantation

Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge (SOHO 2026) - "Treatment was complicated only by transient grade 4 neutropenia, recovering within 3–5 days with filgrastim...Ruxolitinib was started with initial count normalization...The patient received 1 cycle of obinutuzumab plus DHAP... This case highlights marrow-dominant aggressive progression of high-risk CLL/SLL after reactive myelofibrosis, creating a clinically relevant diagnostic dilemma between blastoid CLL/SLL progression and Richter transformation. It underscores the need for integrated morphologic, immunophenotypic, molecular, and clinical assessment, especially where limited access to targeted therapy influences disease trajectory and treatment selection. CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL: chronic lymphocytic leukemia; COVID-19: coronavirus disease 2019; DHAP: dexamethasone, cytarabine, and cisplatin; IGHV: immunoglobulin heavy chain variable region; JAK2: Janus kinase 2; SLL: small lymphocytic lymphoma; TP53: tumor protein p53."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelofibrosis • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • IGH • JAK2 • TP53

Losing More Than Fluid: Diuretic-Associated Agranulocytosis (ACG 2026) - "Introduction: Management of ascites in decompensated cirrhosis includes routine diuretic therapy such as furosemide and spironolactone...The patient was maintained on an increased dose of filgrastim and diuresed with ethacrynic acid instead, with noted improvement in ANC (Table 1)...Figure: Figure 1: Bone marrow core biopsy (H&E, Ã400) showing hypercellular marrow with selective granulocytic aplasia and compensatory erythroid and megakaryocytic hyperplasia. Figure: Table 1: Time course of diuretic administration and filgrastim treatment, white blood cell count, and absolute neutrophil count, demonstrating recovery of agranulocytosis following diuretic discontinuation."

Agranulocytosis • Fibrosis • Granulocytopenia • Hepatology • Immunology • Infectious Disease • Neutropenia

Chronic Graft-Versus-Host Disease Following Intestine, Liver, Pancreas, and Stomach Transplantation (ACG 2026) - "Therapy escalates from everolimus and octreotide to capecitabine and temozolomide, with subsequent disease progression...Dermatology and hematology are consulted, topical steroids are started for the rash and tbo-filgrastim for worsening neutropenia...After refusing cytogam, he returns with rising CMV levels, is treated with IV ganciclovir, and discharged with oral valganciclovir...Persistent donor predominance on STR analysis with cutaneous and bone marrow involvement is shown. Treatment includes corticosteroids, etanercept, photopheresis, ruxolitinib, and supportive care."

Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Gastrointestinal Neuroendocrine Tumor • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Leukopenia • Neuroendocrine Tumor • Neutropenia • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • Solid Tumor • Transplantation

Neutropenic Enterocolitis Presenting as Hemorrhagic Shock in an Encephalopathic Patient With CNS Lymphoma (ACG 2026) - "Pancytopenia resolved with filgrastim and broad-spectrum antibiotics. Figure: Figure 2. ANC over time demonstrating neutropenic nadir (0.13 Ã10³/µL, 3/28) following cyclophosphamide, with lower gastrointestinal hemorrhage occurring six weeks later (5/10) after full hematologic recovery."

Clinical • B Cell Lymphoma • Cardiovascular • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Pulmonary Embolism • Respiratory Diseases

Efficacy and safety of sacituzumab govitecan in patients with metastatic HR+/HER2- pleomorphic lobular breast cancer complicated by renal impairment. (PubMed, Recenti Prog Med) - "Following multidisciplinary evaluation, sacituzumab govitecan was initiated in December 2025 at full dose (10 mg/kg), with primary prophylaxis using filgrastim. The patient is currently continuing treatment with overall good tolerability. This case highlights the feasibility of a personalized approach with sacituzumab govitecan in frail patients with severe renal impairment and lobular breast cancer, populations underrepresented in clinical trials."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer. (ASCO-GI 2023) - P2 | " Eligibility included measurable CRC previously treated with all approved drugs per TAS package insert (irinotecan, oxaliplatin, 5FU, anti-VEGF, anti-EGF) as appropriate, PS = 0-1, labs within usual range, neuropathy < grade 2, ability to take oral meds, appropriate contraception...For the first 40 pts, 385 cycles were given (mean = 7 cycles, median 8) with 18 pts (45%) requiring dose reductions (1 dose reduction = 9 pts, 2 = 6, 3 = 3), and 9 receiving (peg)/filgrastim... In patients with late-line CRC and candidates for TAS (trifluridine/tipiracil), treatment with TAS plus OX is both well tolerated and active. RR is higher than single agent and 78% (95% CI, 60-91%) of patients had stable disease or response, with 60% receiving 8 or more cycles. Randomized trials comparing to single agent TAS are warranted in this setting."

P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML. (ASCO 2024) - P1/2 | "Induction comprised fludarabine 30mg/m 2 D2–6, cytarabine 1.5g/m 2 D2–6, idarubicin 8 (6 if RR) mg/m 2 D4–6 & filgrastim 5mcg/kg D1–7. FLAG-IDA+VEN results in high MRD negative response rates, leading to impressive survival outcomes across ELN risk groups in ND AML. It is an effective salvage regimen for RR AML, especially for S1+TP53 WT pts."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Gastrointestinal Disorder • Infectious Disease • Septic Shock • Transplantation • TP53

A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors. (ASCO 2024) - P1 | "The anti-HER2 CAR-M cell therapy product, CT-0508, is currently being evaluated in a Phase I trial as a monotherapy and in combination with pembrolizumab...Filgrastim mobilized autologous CD14+ monocytes are collected by apheresis, followed by manufacturing and cryopreservation...CT-0525 will be administered without conditioning chemotherapy. Primary endpoints include assessment of safety and tolerability, as well as manufacture feasibility. Correlative assessments include pre- and post-treatment biopsies and blood samples for safety, immunogenicity, pharmacokinetics, tumor trafficking, TME modulation, epitope spreading, and other translational biomarkers."

P1 data • Oncology • Solid Tumor • CD14

FLAG-IDA + VENETOCLAX (VEN) IN NEWLY DIAGNOSED (ND) OR RELAPSED / REFRACTORY (RR) AML (EHA 2024) - "Induction comprised fludarabine 30mg/m2 D2 – 6, cytarabine 1.5g/m2 D2 – 6, idarubicin 8mg/m2 ( 6mg/m2 if RR ) D4 – 6 and filgrastim 5mcg/kg D1 – 7. FLAG-IDA+VEN results in high MRD negative response rates, leading to impressive survival outcomes across ELN risk groups in ND AML. It is an effective salvage regimen for RR AML, especially for TP53 WT pts in first salvage."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Gastrointestinal Disorder • Infectious Disease • Septic Shock • Transplantation • TP53

CarMob: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Sep 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP (ASH 2022) - "Introduction: The CCTG LY.12 trial established rituximab combined with gemcitabine, dexamethasone and cisplatin (R-GDP) as a standard salvage chemotherapy option prior to ASCT for patients (pts) with relapsed/refractory (RR) DLBCL (Crump JCO 2014)...This report involves the component of the trial that randomly allocated pts to either 1 cycle of inpatient R-DICEP (Rituximab 375mg/m2 IV or 1400mg sc days 1 and 5 plus dose-intensive Cyclophosphamide 5.25g/m2, Etoposide 1050mg/m2, Cisplatin 105mg/m2 divided over days 2-4, with daily filgrastim starting day 15 until apheresis of blood stem cells approximately between days 20-22) or to 3 cycles of outpatient R-GDP... Although the 17% improvement in ORR for R-DICEP vs R-GDP in the second interim analysis exceeded the pre-specified 10% threshold required proceed to full accrual of 64 pts in the R-DICEP arm, we decided to stop accrual to the R-DICEP arm of the LY.17 trial due to slow accrual, higher AE rates, and greater..."

Clinical • P2 data • Atrial Fibrillation • Bone Marrow Transplantation • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Transplantation

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia (ASH 2022) - "Induction consisted of fludarabine (30mg/m2, D2-6), cytarabine (1.5g/m2 D2-6), idarubicin (6mg/m2, D4-5), and Filgrastim(D1-7)...Among responding pts, 13 (68%) proceeded to allogeneic transplant, including two pts who transitioned to HMA + VEN and sorafenib maintenance, respectively prior to transplant... In a cohort of pts with R/R AML enriched for fit pts with adverse-risk disease, this intensive combination resulted in an ORR of 60% with a CRc of 53%. Seventy-one percent of CRc pts attained an MRD negative remission and 68% of responding pts proceeded to transplant. In conclusion, this regimen is associated with deep remissions and a high rate of transition to transplant inpatients with R/R AML, particularly in TP53 wild-type."

IO biomarker • P2b data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Transplantation • TP53

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1 | N=46 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

A-TANGO Phase 2 Study (clinicaltrials.gov) - P2 | N=78 | Recruiting | Sponsor: Yaqrit Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Feb 2026 ➔ Aug 2028

Enrollment open • Trial completion date • Trial primary completion date • Fibrosis • Gastroenterology • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov) - P2 | N=16 | Recruiting | Sponsor: Leland Metheny | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • IDH1 • IDH2

Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM (clinicaltrials.gov) - P1/2 | N=10 | Enrolling by invitation | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Dermatology • Gene Therapies • Neutropenia

Methimazole-Induced Agranulocytosis: A Case Report (ETA 2026) - "Treatment was initiated with piperacillin/tazobactam, filgrastim, and propylthiouracil (PTU) 200 mg every 8h, and methimazole was discontinued...PTU was discontinued, and propranolol 10 mg every 8h, hydrocortisone 100 mg every 8h, and cholestyramine 4 g every 8h were initiated... Routine monitoring of leukocyte counts is not recommended, as agranulocytosis occurs abruptly. Given its potential severity, it is essential to inform patients about warning signs and symptoms at the initiation of treatment with thionamides."

Case report • Clinical • Agranulocytosis • Dysphonia • Endocrine Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Granulocytopenia • Grave’s Disease • Hematological Disorders • Infectious Disease • Leukopenia • Mood Disorders • Neutropenia • Otorhinolaryngology

Crescentic transformation induced by granulocyte-colony stimulating factor administration-a case report and review of the literature. (PubMed, Clin Kidney J) - "Here, we present a case of a 48-year-old man with monoclonal gammopathy of renal significance who received filgrastim for planned autologous stem cell transplantation and developed acute kidney injury presenting as crescentic glomerulonephritis. The patient was treated with steroids, plasmapheresis, and cyclophosphamide...When G-CSF is administered to patients with an underlying renal pathology (usually autoimmune or monoclonal in aetiology), the migration and degranulation of activated neutrophils in the glomerular microenvironment in large numbers results in glomerular basement membrane rupture and crescent formation. Timely renal biopsy and aggressive initiation of treatment aid in attaining renal recovery and a favourable prognosis in cancer patients."

Journal • Acute Kidney Injury • Glomerulonephritis • Immunology • Lupus Nephritis • Monoclonal Gammopathy • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease • Transplantation

Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim. (PubMed, Blood Adv) - "This comprehensive study of long-term effects of filgrastim in unrelated donors of peripheral blood stem cells provides strong evidence that donors who receive filgrastim are not at increased risk of these events compared to bone marrow donors. It also provides reassurance to current donors undergoing stem cell mobilization as well as individuals considering joining stem cell registries such as NMDP."

Journal • Cardiovascular • Immunology • Thrombosis • Transplantation

Early vs Late Granulocyte Colony-Stimulating Factor Initiation and Hospital Length of Stay in Adult Inpatients With Severe Neutropenia: A Retrospective Cohort Study (SOHO 2026) - "Interventions: Filgrastim or approved biosimilar; dichotomized as early (≤24 hours) vs late (>24 hours) initiation relative to hospital admission... Among hospitalized adults with severe neutropenia receiving G-CSF, initiation within 24 hours of admission was associated with a clinically meaningful LOS reduction without increased 30-day readmission. These findings suggest that once therapeutic G-CSF is elected, early administration may reduce inpatient utilization. Multicenter prospective studies are warranted to confirm this association and assess generalizability."

Retrospective data • Oncology

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: St. Jude Children's Research Hospital | Initiation date: Jun 2026 ➔ Nov 2026

Trial initiation date • Aplastic Anemia • Hematological Disorders